{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:11:15Z","timestamp":1773839475471,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00535-016-1174-4","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T06:53:34Z","timestamp":1455260014000},"page":"741-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis"],"prefix":"10.1007","volume":"51","author":[{"given":"Hidenori","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Zeniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,12]]},"reference":[{"issue":"5","key":"1174_CR1","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.22545","volume":"48","author":"M Berenguer","year":"2008","unstructured":"Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48(5):1690\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"1174_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","volume":"36","author":"F Fabrizi","year":"2002","unstructured":"Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36(1):3\u201310.","journal-title":"Hepatology"},{"issue":"4","key":"1174_CR3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2008.06.003","volume":"49","author":"P Martin","year":"2008","unstructured":"Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49(4):613\u201324.","journal-title":"J Hepatol"},{"issue":"2","key":"1174_CR4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","volume":"26","author":"CH Liu","year":"2011","unstructured":"Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol. 2011;26(2):228\u201339.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1174_CR5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0272-6386(98)70027-7","volume":"32","author":"CO Stehman-Breen","year":"1998","unstructured":"Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32(4):629\u201334.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1174_CR6","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","volume":"53","author":"BJ Pereira","year":"1998","unstructured":"Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int. 1998;53(5):1374\u201381.","journal-title":"Kidney Int"},{"issue":"8","key":"1174_CR7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/16.8.1669","volume":"16","author":"M Espinosa","year":"2001","unstructured":"Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. Risk of death and liver cirrhosis in anti-HCV positive long-term hemodialysis patients. Nephrol Dial Transplant. 2001;16(8):1669\u201374.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"1174_CR8","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1681\/ASN.V11101896","volume":"11","author":"E Nakayama","year":"2000","unstructured":"Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11(10):1896\u2013902.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1174_CR9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216\u201324.","journal-title":"N Engl J Med"},{"issue":"3","key":"1174_CR10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):724\u20138.","journal-title":"Hepatology"},{"issue":"6","key":"1174_CR11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1 infection. Hepatology. 2014;59(6):2083\u201391.","journal-title":"Hepatology"},{"issue":"5","key":"1174_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP2941","volume":"20","author":"T Garimella","year":"2015","unstructured":"Garimella T, Wang R, Luo WL, et al. Single-dose pharmacokinetics and safety of daclatasvir in subject with renal function impairment. Antivir Ther. 2015;20(5):535\u201343.","journal-title":"Antivir Ther"},{"issue":"10","key":"1174_CR13","first-page":"430A","volume":"58","author":"T Garimella","year":"2013","unstructured":"Garimella T, He B, Luo WL, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. Hepatology. 2013;58(10):430A.","journal-title":"Hepatology"},{"issue":"1","key":"1174_CR14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.35.1.201-207.1997","volume":"35","author":"O Ohno","year":"1997","unstructured":"Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35(1):201\u20137.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"1174_CR15","doi-asserted-by":"crossref","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9(11):e112647.","journal-title":"PLoS One"},{"issue":"3","key":"1174_CR16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcv.2005.09.010","volume":"35","author":"EPA Lopes","year":"2006","unstructured":"Lopes EPA, Gouveia EC, Albuquerque ACC, et al. Determination of the cut-off of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol. 2006;35(3):298\u2013302.","journal-title":"J Clin Virol"},{"issue":"6","key":"1174_CR17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1174_CR18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1159\/000188520","volume":"69","author":"JY Guh","year":"1995","unstructured":"Guh JY, Lai YH, Yang CY, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis patients. Nephron. 1995;69(4):459\u201365.","journal-title":"Nephron."},{"issue":"2","key":"1174_CR19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004836-200003000-00012","volume":"30","author":"N Yuki","year":"2000","unstructured":"Yuki N, Ishida H, Inoue T, et al. Reappraisal of biochemical hepatitis C activity in hemodialysis patients. J Clin Gastroenterol. 2000;30(2):187\u201394.","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"1174_CR20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","volume":"159","author":"CH Liu","year":"2013","unstructured":"Liu CH, Huang CF, Liu CJ, et al. Pegylated interferon-\u03b12a with or without low-dose ribavirin for treatment-na\u00efve patients with hepatitis C virus genotype 1 receiving hemodialysis. A randomized trial. Ann Intern Med. 2013;159(11):729\u201338.","journal-title":"Ann Intern Med."},{"issue":"4","key":"1174_CR21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1365-2036.2011.04741.x","volume":"34","author":"P Deltenre","year":"2011","unstructured":"Deltenre P, Moreno C, Tran A, et al. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Alim Pharmacol Ther. 2011;34(4):454\u201361.","journal-title":"Alim Pharmacol Ther."},{"issue":"9","key":"1174_CR22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/jmv.21858","volume":"82","author":"H Toyoda","year":"2010","unstructured":"Toyoda H, Kumada T, Kiriyama S, et al. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1. J Med Virol. 2010;82(9):1537\u201344.","journal-title":"J Med Virol"},{"issue":"6","key":"1174_CR23","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1440-1746.2010.06240.x","volume":"25","author":"H Toyoda","year":"2010","unstructured":"Toyoda H, Kumada T, Tada T, et al. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol. 2010;25(6):1072\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"1174_CR24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1872-034X.2007.00117.x","volume":"37","author":"K Fujiwra","year":"2007","unstructured":"Fujiwra K, Kaneko S, Kakumu S, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007;37(9):701\u201310.","journal-title":"Hepatol Res."},{"issue":"11","key":"1174_CR25","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1872-034X.2010.00708.x","volume":"40","author":"S Kaneko","year":"2010","unstructured":"Kaneko S, Sata M, Ide T, et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Hepatol Res. 2010;40(11):1072\u201381.","journal-title":"Hepatol Res."},{"issue":"11\u201312","key":"1174_CR26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2003.01780.x","volume":"18","author":"F Fabrizi","year":"2003","unstructured":"Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18(11\u201312):1071\u201381.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1174_CR27","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","volume":"98","author":"MW Russo","year":"2003","unstructured":"Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98(7):1610\u20135.","journal-title":"Am J Gastroenterol"},{"key":"1174_CR28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","volume":"8","author":"AG Singal","year":"2010","unstructured":"Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1174_CR29","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124\u201330.","journal-title":"Hepatology"},{"key":"1174_CR30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","volume":"129","author":"Y Imai","year":"1998","unstructured":"Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94\u20139.","journal-title":"Ann Intern Med"},{"key":"1174_CR31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"1174_CR32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.510270529","volume":"27","author":"A Kasahara","year":"1998","unstructured":"Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394\u2013402.","journal-title":"Hepatology"},{"key":"1174_CR33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","volume":"58","author":"E Ogawa","year":"2013","unstructured":"Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective multicenter study. J Hepatol. 2013;58:495\u2013501.","journal-title":"J Hepatol"},{"key":"1174_CR34","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u201393.","journal-title":"JAMA"},{"key":"1174_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469\u201377.","journal-title":"J Infect Dis"},{"key":"1174_CR36","doi-asserted-by":"crossref","unstructured":"Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int (in press).","DOI":"10.1111\/liv.13071"},{"key":"1174_CR37","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/jmv.24160","volume":"87","author":"J Tanaka","year":"2015","unstructured":"Tanaka J, Katayama K, Matsuo J, et al. The association of hepatitis C virus infection with the prognosis of chronic hemodialysis patients: a retrospective study of 3,064 patients between 1999 and 2010. J Med Virol. 2015;87:1558\u201364.","journal-title":"J Med Virol"},{"issue":"10","key":"1174_CR38","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchefeld A, et al. Grazoprevir plus elbasvir in treatment-na\u00efve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386(10):1537\u201345.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1174_CR39","first-page":"S1145A","volume":"62","author":"PJ Pockros","year":"2015","unstructured":"Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCVGT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. J Hepatol. 2015;62(Suppl 1):S1145A.","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1007\/s00535-016-1192-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,3,7]],"date-time":"2016-03-07T00:00:00Z","timestamp":1457308800000}}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-016-1174-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1174-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:25:18Z","timestamp":1654302318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-016-1174-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,12]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1174-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,12]]}}}